Monitor for final pricing and Nasdaq listing approval. The small float (~4.5M shares) and micro-cap nature (~$20M at midpoint) could drive significant first-day volatility. Track post-IPO execution against use-of-proceeds plan, particularly B2B expansion and regional growth in Southeast Asia. The dual-class structure with 85%+ voting control by insiders limits shareholder influence.
Executive Summary
Neucleus Group Ltd filed Amendment No. 2 to its F-1 registration statement for an IPO of 4,500,000 Class A Ordinary Shares at an estimated $4-$5 per share on the Nasdaq under ticker 'NEUC'. The Cayman Islands holding company operates through its Malaysian subsidiary Dami Strategies, providing scientific parental consultation services using DNA testing and expert consultations. The company generated $3.1M revenue in FY2025 (up 1,030% YoY) and $937.7M net income, with net proceeds of ~$17.6M expected to fund service expansion, marketing, regional growth, and working capital.
Key Financial Metrics
Key Facts
- Offering 4,500,000 Class A Ordinary Shares at $4-$5 per share, with 675,000-share over-allotment option
- Post-IPO shares: 23,100,000 Class A + 3,000,000 Class B (26,100,000 total); Class B has 20 votes per share vs 1 for Class A
- Controlling shareholder Neucleus Dami Sdn. Bhd. will own ~53.64% of shares and ~85.44% of voting power post-IPO
- FY2025 revenue $3,098,307 (up from $274,084 in FY2024); net income $937,688 (up from $53,508)
- H1 FY2026 (6 months ended Dec 31, 2025) revenue $2,895,149 (up 101% YoY); net income $1,014,171 (up 128%)
- Net proceeds estimated at ~$17.6M (midpoint $4.50/share): 35% service development, 25% sales/marketing, 20% regional expansion, 20% working capital
- Dual-class structure with no sunset provision on Class B super-voting shares
- Nasdaq listing approval not yet obtained; closing conditional on final approval
- Total cash expenses for offering estimated at ~$1,036,996 exclusive of underwriting discounts
- Underwriters: Network 1 Financial Securities (representative); 7% underwriting discount plus 1% non-accountable expense allowance
Financial Impact
Net proceeds of ~$17.6M from IPO at $4.50 midpoint, representing ~10.6x FY2025 revenue and ~18.8x FY2025 net income at the offering valuation
Risk Factors
- Limited operating history since 2022 with only $3.1M annual revenue; unproven scalability
- Concentration risk: all operations in Malaysia, subject to political, economic, and FX risks
- Dual-class structure gives controlling shareholder ~85% voting power with no sunset provision
- Nasdaq listing not yet approved; offering conditional on final approval
- Potential PFIC status for US investors with adverse tax consequences
- Management lacks US public company experience; compliance costs will increase significantly
- Supplier concentration: one supplier accounted for 77-89% of cost of sales
- Trade receivables surged to $1.42M (Dec 2025) from $439K (Jun 2025); credit risk increasing
- No insurance coverage; no dividend policy; penny stock risk if price falls below $4
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001493152-26-033344 |
| Exhibit: ex10-4.htm | 0001493152-26-033344 |
| Exhibit: ex99-9.htm | 0001493152-26-033344 |
| Document: 0001493152-26-033344-index-headers.html | 0001493152-26-033344 |
| Document: 0001493152-26-033344-index.html | 0001493152-26-033344 |
| Document: 0001493152-26-033344.txt | 0001493152-26-033344 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers